SecBot SecBot
SECBOTREPLAY Home › Report › CRVS

CRVS · Corvus Pharmaceuticals filed a definitive proxy statement (DEFA14A) for…

Corvus Pharmaceuticals, Inc. · DEFA14A filed Apr 24, 2026 at 16:16 ET

At the news

NEUTRALIMPACT 4/10

DEFA14A filed Apr 24, 2026 at 16:16 ET

Corvus Pharmaceuticals filed a definitive proxy statement (DEFA14A) for its 2026 Annual Meeting, which includes proposals to elect two Class I Directors, ratify the selection of PricewaterhouseCoopers LLP as the independent auditor, and approve the compensation of named executive officers. This filing follows the recent appointment of Dr. Andrew Chan to the board and the resignation of Scott Morrison, indicating board changes near the proxy materials. The vote is non-binding on executive compensation.

  • The proxy statement is for the 2026 Annual Meeting of Stockholders, scheduled for June 11, 2026.
  • Proposals include the election of two Class I Directors, ratification of PricewaterhouseCoopers LLP as the independent auditor, and approval of named executive officer compensation.
  • The board recommends a vote FOR all proposals.
  • This filing follows an 8-K filing on April 23, 2026, which announced the appointment of Dr. Andrew Chan to the board and the resignation of Scott Morrison.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access